JP5834010B2 - ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 - Google Patents
ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 Download PDFInfo
- Publication number
- JP5834010B2 JP5834010B2 JP2012532579A JP2012532579A JP5834010B2 JP 5834010 B2 JP5834010 B2 JP 5834010B2 JP 2012532579 A JP2012532579 A JP 2012532579A JP 2012532579 A JP2012532579 A JP 2012532579A JP 5834010 B2 JP5834010 B2 JP 5834010B2
- Authority
- JP
- Japan
- Prior art keywords
- langerhans
- medicament
- islets
- transplantation
- reparixin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004153 islets of langerhan Anatomy 0.000 title claims description 57
- 238000002054 transplantation Methods 0.000 title claims description 55
- 239000002671 adjuvant Substances 0.000 title claims description 12
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 title description 16
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 title description 16
- 239000003112 inhibitor Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 230000004083 survival effect Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- -1 4-isobutylphenyl Chemical group 0.000 claims description 7
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 230000007774 longterm Effects 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000007257 malfunction Effects 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 53
- 229950005650 reparixin Drugs 0.000 description 53
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 42
- 239000008103 glucose Substances 0.000 description 42
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 23
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 23
- 229960002930 sirolimus Drugs 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 18
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 9
- 235000020925 non fasting Nutrition 0.000 description 9
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 8
- 102100022338 Integrin alpha-M Human genes 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 7
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 6
- 102100022297 Integrin alpha-X Human genes 0.000 description 6
- 102100026236 Interleukin-8 Human genes 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000003622 mature neutrocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940124589 immunosuppressive drug Drugs 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 238000002650 immunosuppressive therapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NVCLUVQEABCKKJ-UHFFFAOYSA-N 2-oxobutane-1-sulfonamide Chemical compound CCC(=O)CS(N)(=O)=O NVCLUVQEABCKKJ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101100182715 Mus musculus Ly6c2 gene Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172364A EP2308484A1 (en) | 2009-10-06 | 2009-10-06 | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP09172364.3 | 2009-10-06 | ||
| PCT/EP2010/064921 WO2011042466A1 (en) | 2009-10-06 | 2010-10-06 | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015077750A Division JP6097328B2 (ja) | 2009-10-06 | 2015-04-06 | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506704A JP2013506704A (ja) | 2013-02-28 |
| JP2013506704A5 JP2013506704A5 (enExample) | 2013-11-28 |
| JP5834010B2 true JP5834010B2 (ja) | 2015-12-16 |
Family
ID=41818891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532579A Expired - Fee Related JP5834010B2 (ja) | 2009-10-06 | 2010-10-06 | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
| JP2015077750A Expired - Fee Related JP6097328B2 (ja) | 2009-10-06 | 2015-04-06 | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015077750A Expired - Fee Related JP6097328B2 (ja) | 2009-10-06 | 2015-04-06 | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20120202884A1 (enExample) |
| EP (2) | EP2308484A1 (enExample) |
| JP (2) | JP5834010B2 (enExample) |
| KR (2) | KR101817912B1 (enExample) |
| CN (2) | CN104906572A (enExample) |
| AU (1) | AU2010305385B2 (enExample) |
| BR (1) | BR112012007991B8 (enExample) |
| CA (1) | CA2775902C (enExample) |
| CY (1) | CY1115018T1 (enExample) |
| DK (1) | DK2485723T3 (enExample) |
| EA (1) | EA021298B1 (enExample) |
| ES (1) | ES2451349T3 (enExample) |
| HK (1) | HK1213777A1 (enExample) |
| HR (1) | HRP20140202T1 (enExample) |
| IL (1) | IL219037A (enExample) |
| ME (1) | ME01719B (enExample) |
| MX (1) | MX2012004082A (enExample) |
| NZ (1) | NZ599172A (enExample) |
| PL (1) | PL2485723T3 (enExample) |
| PT (1) | PT2485723E (enExample) |
| RS (1) | RS53249B (enExample) |
| SI (1) | SI2485723T1 (enExample) |
| SM (1) | SMT201400033B (enExample) |
| WO (1) | WO2011042466A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015145404A (ja) * | 2009-10-06 | 2015-08-13 | ドムペ・ソチエタ・ペル・アツィオーニ | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| CN103159652B (zh) * | 2011-12-19 | 2016-06-08 | 天津市国际生物医药联合研究院 | 亚磺酰胺类化合物的制备及其应用 |
| CN105722972A (zh) | 2013-06-18 | 2016-06-29 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点 |
| CN109890364B (zh) | 2016-10-03 | 2023-10-17 | 儿童医疗中心公司 | 糖尿病肾病的预防和治疗 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| US20020042370A1 (en) * | 2000-04-14 | 2002-04-11 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CCR2 function |
| WO2001078708A1 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Treating graft rejection with cxcr3 inhibitors |
| ITMI20010206A1 (it) | 2001-02-02 | 2002-08-02 | Dompe Spa | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
| PT1776336E (pt) * | 2004-03-23 | 2009-12-18 | Dompe Spa | Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm |
| EP1579859B1 (en) | 2004-03-25 | 2006-12-13 | DOMPE' pha.r.ma s.p.a. | Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
| US20050261762A1 (en) * | 2004-05-21 | 2005-11-24 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
| TWI400232B (zh) * | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
| JP5232144B2 (ja) * | 2006-06-28 | 2013-07-10 | サノフイ | Ｃｘｃｒ２阻害剤 |
| JP2010504996A (ja) * | 2006-09-26 | 2010-02-18 | ケース ウエスタン リザーブ ユニバーシティ | サイトカインシグナリング |
| WO2009117706A2 (en) | 2008-03-20 | 2009-09-24 | Carolus Therapeutics, Inc. | Methods of treatment using anti-mif antibodies |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
-
2009
- 2009-10-06 EP EP09172364A patent/EP2308484A1/en not_active Withdrawn
-
2010
- 2010-10-06 ME MEP-2014-24A patent/ME01719B/me unknown
- 2010-10-06 DK DK10761018.0T patent/DK2485723T3/en active
- 2010-10-06 KR KR1020177015626A patent/KR101817912B1/ko not_active Expired - Fee Related
- 2010-10-06 EA EA201270513A patent/EA021298B1/ru unknown
- 2010-10-06 CN CN201510089937.5A patent/CN104906572A/zh active Pending
- 2010-10-06 HR HRP20140202AT patent/HRP20140202T1/hr unknown
- 2010-10-06 JP JP2012532579A patent/JP5834010B2/ja not_active Expired - Fee Related
- 2010-10-06 RS RS20140102A patent/RS53249B/sr unknown
- 2010-10-06 MX MX2012004082A patent/MX2012004082A/es active IP Right Grant
- 2010-10-06 PT PT107610180T patent/PT2485723E/pt unknown
- 2010-10-06 CN CN201080045208.5A patent/CN102665703B/zh not_active Expired - Fee Related
- 2010-10-06 ES ES10761018.0T patent/ES2451349T3/es active Active
- 2010-10-06 AU AU2010305385A patent/AU2010305385B2/en not_active Ceased
- 2010-10-06 CA CA2775902A patent/CA2775902C/en not_active Expired - Fee Related
- 2010-10-06 KR KR1020127010732A patent/KR101759362B1/ko not_active Expired - Fee Related
- 2010-10-06 US US13/500,544 patent/US20120202884A1/en not_active Abandoned
- 2010-10-06 PL PL10761018T patent/PL2485723T3/pl unknown
- 2010-10-06 SI SI201030553T patent/SI2485723T1/sl unknown
- 2010-10-06 WO PCT/EP2010/064921 patent/WO2011042466A1/en not_active Ceased
- 2010-10-06 NZ NZ599172A patent/NZ599172A/en not_active IP Right Cessation
- 2010-10-06 EP EP10761018.0A patent/EP2485723B1/en active Active
- 2010-10-06 BR BR112012007991A patent/BR112012007991B8/pt not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219037A patent/IL219037A/en active IP Right Grant
-
2014
- 2014-03-07 CY CY20141100185T patent/CY1115018T1/el unknown
- 2014-03-19 SM SM201400033T patent/SMT201400033B/xx unknown
-
2015
- 2015-04-06 JP JP2015077750A patent/JP6097328B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-18 HK HK16101720.7A patent/HK1213777A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015145404A (ja) * | 2009-10-06 | 2015-08-13 | ドムペ・ソチエタ・ペル・アツィオーニ | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6097328B2 (ja) | ランゲルハンス島の移植におけるアジュバントとしてのｃｘｃｒ１／２の阻害薬 | |
| EP1772145A1 (en) | Method of effectively using medicine and method concerning prevention of side effect | |
| KR20140124023A (ko) | 보체 활성을 저해함으로써 동종이식편의 생존 연장 | |
| US20110104173A1 (en) | Inhibition of degradation of extracellular matrix | |
| Lee et al. | The effect of whole organ pancreas transplantation and PIT on diabetic complications | |
| JP5745526B2 (ja) | 糖尿病の予防のためのスルホンアミド | |
| US20180030048A1 (en) | Compounds and methods to suppress autoimmune response | |
| EP3878443A1 (en) | Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor | |
| US20210093586A1 (en) | Method of reducing neuronal cell death with haloalkylamines | |
| HK1175993B (en) | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets | |
| US20250295638A1 (en) | Methods of treating allograft rejection | |
| WO2007089716A2 (en) | Use of aminopyrimidine compounds in the treatment of immune disorders | |
| Aronson | MG Franzosi and R. Latini | |
| HK1174557B (en) | Sulfonamides for the prevention of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131007 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131007 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141006 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150406 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150406 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20150904 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151030 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5834010 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |